Antagonistic effect of yangambin on platelet-activating factor (PAF)-induced cardiovascular collapse

Phytomedicine

Volumn 2, Issue 3, 1996, Pages 235-242

  Tibirica, E V ^a   Mosquera, K ^a   Abreu, M ^a   Ribeiro, R ^a   Carvalho, F A ^a   Barbosa Filho, J M ^a   Cordiero, R S ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

OCOTEA; OCOTEA DUCKEI;

EID: 0030052173     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0944-7113(96)80048-1     Document Type: Article

References (40)

1. K.F. Austen The anaphylactic syndrome M. Sampter Immunological Diseases 1978 Little & Brown Boston 885 899
2. A. Bernat J.M. Herbert V. Salel L. Lespy P. Maffrand Protective effects of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea pig J. Lipid Mediators 51 1992 41 48
3. P. Bessin J. Bonnet D. Apffel C. Soulard L. Desgroux I. Pelas J. Benveniste Acute circulatory collapse caused by plateletactivating factor (PAF-acether) in dogs Eur. J. Pharmacol. 86 1983 403 413
4. M.L. Blank E. Snyder L.W. Byers B. Brooks E.E. Muirhead Antihypertensive activity of an alkyl ether analog of phsophatidylcholine Biochem. Biopbys. Res. Commun. 90 1979 1194 1200
5. B.H. Booth Electrocardiographic changes during human anaphylaxis JAMA 211 1970 627 631
6. P. Braquet D. Hosford Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents J. Ethnopharmacol. 32 1991 135 139
7. P. Braquet L. Touqui T.Y. Shen B.B. Vargaftig Perspectives in platelet-activating factor research Pharmacol. Rev. 39 1987 97 145
8. C.G. Caillard S. Mondot J.L. Zundel L. Julou Hypotensive activity of PAF-acether in rats Agents and Actions 12 1982 725 730
9. G. Camussi G. Alloatti G. Montrucchio M. Meda G. Emmanuelli Effect of platelet-activating factor on guinea-pig papillary muscle Experientia 40 1984 357 361
10. J. Casals-Stenzel Protective effect of WEB 2086, a novel antagonist of platelet-activating factor, in endotoxin shock Eur. J. Pharmacol. 135 1987 117 122
11. J. Casals-Stenzel G. Muacevic K.H. Weber Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor J. Pharmacol. Exp. Ther. 241 1987 974 981
12. H.C. Castro-Faria-Neto M.A. Martins P.M.R. Silva P. Bozza H.N. Cruz M. De Queiroz-Paulo M.A.C. Kaplan R.S.B. Cordeiro Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity J. Lipid Mediators 7 1993 1 9
13. H.C. Castro-Faria-Neto P.T. Bozza G. Thomas H.N. Cruz C.L.M. Silva F. Violante G. Thomas J.M. Barbosa-Filho M.A. Martins E. Tibiriçá F. Noel R.S.B. Cordeiro Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: in vitro pharmacological studies Planta Med 61 1995 101 105
14. H.C. Castro-Faria-Neto C.V. Araújo S. Moreira B.T. Bozza G. Thomas J.M. Barbosa-Filho R.S.B. Cordeiro E. Tibiriçá Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies Planta Med 61 1995 106 112
15. M. De Queiroz-Paulo M.A.C. Kaplan O. Laprevote F. Roblot R. Hocquemiller A. Cave Lignans and other non-alkaloidal constituents from Rollinea mucosa Fitoterapia 62 1991 150 152
16. E.A. Deitch Multiple organ failure: pathophysiology and potential future therapy Ann. Surg. 216 1992 117 134
17. L.M. Delbridge A.G. Stewart C.M. Goulter T.O. Morgan P.J. Harris Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility J. Mol. Cell. Cardiol. 26 1994 185 193
18. S.B. Felix G. Baumann P. Raschke C. Maus W.E. Berdel Cardiovascular reactions and respiratory events during platelet activating factor-indcued shock Basic Res. Cardiol. 85 1990 217 226
19. P. Guinot C. Brambilla J. Duchier P. Braquet B. Bonvoisin A. Cournot Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients: a preliminary study Prostaglandins 34 1987 723 731
20. 18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat Life Sci. 49 1991 747 752
21. S.A. Hirsch Acute allergic reaction with coronary vasospasm Am. Heart J. 193 1982 928 932
22. D. Hosford C.P. Page P.J. Barnes P. Braquet PAF-receptors antagonists P.J. Barnes C. Page P.M. Henson Platelet activating factor and human disease 1989 Blackwell Scientific Publications Cambridge 82 116
23. F.R.M. Laurindo R.E. Goldstein N.J. Davenport D. Ezra G.Z. Feuerstein Mechanisms of hypotension produced by platelet-activating factor J. Appl. Physiol. 66 1989 2681 2690
24. R. Levi J.A. Burke Z.G. Guo Y. Hattori C.M. Hoppens L.M. MacManus D.J. Hanahan R.N. Pinckard Acetyl glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig Circ. Res. 54 1984 117 124
25. L.M. MacManus D.J. Hanahan C.A. Demopoulos R.N. Pinckard Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit J. Immunol. 124 1980 2919 2924
26. L.M. MacManus R.N. Pinckard F.A. Fitzpatrick R.A. O’Rourke M.H. Crawford D.J. Hanahan Acetyl glyceril ether phosphorylcholine: intravascular alterations following intravenous infusion into the baboon Lab. Invest. 45 1981 303 307
27. W.D. MacRae G.H.N. Towers Biochemical Activities of the Lignans Phyto chemistry 24 1985 561 566
28. L.M. Mesquita N.F. Roque L.M.B. Quintana M.Q. Paulo J.M. Barbosa-Filho Lignans from Rollinia species Biochem. Syst. Ecol. 16 1988 379 380
29. J.K. Mickelson P.J. Simpson B.R. Lucchesi Myocardial dysfunction and coronary vasoconstriction induced by platelet-activating factor in the post-infarcted rabbit isolated heart J. Mol. Cell. Cardiol. 20 1988 547 561
30. G. Muacevic H.O. Heuer Platelet-activating factor antagonists in experimental shock Arzneim. -Forsch. /Drug Res. 42 1992 1001 1004
31. J. Nagaoka K. Harada A. Kimura S. Kobayashi M. Murakami T. Yoshimura K. Yamada O. Asano K. Katayama I. Yamatsu Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoylN-[(2 R)-2-methoxy-3-(4-octadecylcarbamoyloxy) piperidino-carbonyloxypropyloxy] carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models Arzneim. -Forsch./Drug Res. 41 1991 719 724
32. J.X. Pan O.D. Hensens D.L. Zink M.N. Chang S.B. Hwang Lignans with platelet-activating factor antagonist activity from Magnolia biondii Phytochemistry 26 1987 1377 1379
33. D.A. Robertson A. Genovese R. Levi Negative inotropic effect of platelet-activating factor in human myocardium: A pharmacological study J. Pharmacol. Exp. Ther. 243 1987 834 839
34. D.A. Robertson D.Y. Wang C.O. Lee R. Levi Negative innotropic effect of platelet-activating factor: association with a decrease in intracellular sodium activity J. Pharmacol. Exp. Ther. 245 1988 124 128
35. F. Synder Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators Am. J. Physiol. 259 1990 C697 C 708
36. E.J. Sybertz R.W. Watkins T. Baum K. Pula M. Rivelli Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog J. Pharmacol. Exp. Ther. 232 1985 156 162
37. Z.I. Terashita Y. Imura A. Shino K. Nishikawa A lethal role of platelet-activating factor in anaphylactic shock in mice J. Pharmacol. Exp. Ther. 243 1987 378 383
38. Z.I. Terashita M. Kawamura M. Takatani S. Tsushima Y. Imura K. Nishikawa Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in mice J. Pharmacol. Exp. Ther. 260 1992 748 755
39. Z.I. Terashita S. Tsushima Y. Yoshioka H. Nomura Y. Inada K. Nishikawa CV 3988 — a specific antagonist of platelet-activating factor (PAF) Life Sci. 32 1983 1975 1982
40. S. Yamanaka M. Katsuyuki T. Yukimura M. Okumura K. Yamamoto Putative mechanisms of hypotensive action of platelet-activating factor in dogs Circ. Res. 70 1992 893 901